Industry challenges

Industry challenges

  • Print

Tomorrow’s challenge is to develop new medicines that can prevent or cure currently incurable diseases. Today’s challenge is to get to tomorrow – and that’s a tall order in itself.

Rising customer expectations: The commercial environment is getting harsher, as healthcare payers impose new cost constraints on healthcare providers and scrutinise the value medicines offer much more carefully. They want new therapies that are clinically and economically better than the existing alternatives, together with hard, real-world outcomes data to back any claims about a medicine’s superiority.

Poor scientific productivity: Pharma’s output has remained at a stable level for the past decade. Using the same discovering and developing processes, there’s little reason to think its productivity will suddenly soar.

Cultural sclerosis: The prevailing management culture, mental models and strategies on which the industry relies are the same ones it’s traditionally relied on, even though they’ve been eclipsed by new ways of doing business.

Read more

 

Pharma 2020
From vision to decision

Pharma's incurring bigger and more frequent financial penalties in the US

Pharma 2020
From vision to decision

Pharma's scientific productivity has flatlined for a full decade

Pharma 2020
From vision to decision

Costs per approved molecule are unsustainably high

Pharma 2020
From vision to decision

Most pharma companies spend a very small percentage of their budgets on target selection and validation